Cargando…
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved drug class for the treatment of type 2 diabetes mellitus (T2D). Although they are largely well-tolerated, their intake has been associated with euglycemic diabetic ketoacidosis (DKA) in some rare cases. We report the c...
Autores principales: | Calçada, Marta Brandão, Fernandes, Luís, Soares Costa, Rita, Montezinho, Sara, Martins Duarte, Filipa, Frutuoso, Luísa, Freitas, Ana Raquel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167627/ https://www.ncbi.nlm.nih.gov/pubmed/33917274 http://dx.doi.org/10.3390/clinpract11020031 |
Ejemplares similares
-
Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin
por: Fustiga, João, et al.
Publicado: (2022) -
Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021) -
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019) -
Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports
por: Altowayan, Waleed M.
Publicado: (2022) -
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
por: Candelario, Nellowe, et al.
Publicado: (2016)